TY - JOUR
T1 - Highlights on U.S. FDA-approved halogen-containing drugs in 2024
AU - Ali, Saghir
AU - Tian, Xiaochen
AU - Meccia, Salvatore A.
AU - Zhou, Jia
N1 - Publisher Copyright:
© 2025 Elsevier Masson SAS
PY - 2025/4/5
Y1 - 2025/4/5
N2 - This comprehensive review offers an update on the FDA-approved halogen-containing drugs in 2024. The agency approved a total of 50 drugs, including small molecules and macromolecules. Excitingly, 16 out of 50 are halogen-containing drugs, indicated to diagnose, mitigate and treat the various human diseases. Among halogens, fluorine and chlorine are highly prevalent in drug discovery and development. Therefore, the properties of fluorine and chlorine and their impact on the drug profile are briefly discussed. In addition, the specific role of halogens in these drugs has been discussed with the help of structure-activity relationships (SARs), co-crystal structures, and closely related literature precedents. This review also provides the additional information for each drug, such as trade name, active ingredients, route of administration, approval date, sponsors, indication, mode of action, major drug metabolizing enzyme(s), and route of elimination. We expect that the present review may garner the attention of drug discovery researchers and inspire them toward the potential applications of halogens to discover novel therapeutics in the future.
AB - This comprehensive review offers an update on the FDA-approved halogen-containing drugs in 2024. The agency approved a total of 50 drugs, including small molecules and macromolecules. Excitingly, 16 out of 50 are halogen-containing drugs, indicated to diagnose, mitigate and treat the various human diseases. Among halogens, fluorine and chlorine are highly prevalent in drug discovery and development. Therefore, the properties of fluorine and chlorine and their impact on the drug profile are briefly discussed. In addition, the specific role of halogens in these drugs has been discussed with the help of structure-activity relationships (SARs), co-crystal structures, and closely related literature precedents. This review also provides the additional information for each drug, such as trade name, active ingredients, route of administration, approval date, sponsors, indication, mode of action, major drug metabolizing enzyme(s), and route of elimination. We expect that the present review may garner the attention of drug discovery researchers and inspire them toward the potential applications of halogens to discover novel therapeutics in the future.
KW - Diagnostics
KW - Drug discovery
KW - FDA-Approved drugs
KW - Halogenated drugs
KW - PET imaging
KW - Therapeutics
UR - http://www.scopus.com/inward/record.url?scp=85217429857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85217429857&partnerID=8YFLogxK
U2 - 10.1016/j.ejmech.2025.117380
DO - 10.1016/j.ejmech.2025.117380
M3 - Review article
C2 - 39947048
AN - SCOPUS:85217429857
SN - 0223-5234
VL - 287
JO - European journal of medicinal chemistry
JF - European journal of medicinal chemistry
M1 - 117380
ER -